Pieris Pharmaceuticals Inc (NASDAQ:PIRS) Receives Consensus Rating of “Buy” from Analysts

Pieris Pharmaceuticals Inc (NASDAQ:PIRS) has been assigned a consensus recommendation of “Buy” from the seven ratings firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, three have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among analysts that have covered the stock in the last year is $6.00.

Several equities research analysts have weighed in on the stock. Robert W. Baird downgraded shares of Pieris Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $5.00 target price for the company. in a research note on Tuesday, July 30th. ValuEngine upgraded shares of Pieris Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 29th. Zacks Investment Research upgraded shares of Pieris Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, August 17th. HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Pieris Pharmaceuticals in a research note on Thursday, August 1st. Finally, William Blair restated a “buy” rating on shares of Pieris Pharmaceuticals in a research note on Friday, August 16th.

In other Pieris Pharmaceuticals news, major shareholder Bvf Partners L. P/Il sold 50,000 shares of Pieris Pharmaceuticals stock in a transaction on Friday, September 6th. The shares were sold at an average price of $4.50, for a total value of $225,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 6.59% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC boosted its holdings in Pieris Pharmaceuticals by 1,074.8% in the second quarter. Tower Research Capital LLC TRC now owns 5,874 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 5,374 shares during the period. BNP Paribas Arbitrage SA bought a new stake in shares of Pieris Pharmaceuticals in the 1st quarter worth approximately $36,000. Lindbrook Capital LLC bought a new stake in shares of Pieris Pharmaceuticals in the 2nd quarter worth approximately $37,000. Clear Harbor Asset Management LLC bought a new stake in shares of Pieris Pharmaceuticals in the 2nd quarter worth approximately $47,000. Finally, Jane Street Group LLC bought a new stake in shares of Pieris Pharmaceuticals in the 2nd quarter worth approximately $47,000. 55.11% of the stock is owned by hedge funds and other institutional investors.

PIRS traded up $0.33 during trading on Friday, hitting $5.42. The stock had a trading volume of 473,406 shares, compared to its average volume of 515,118. The company has a market capitalization of $251.41 million, a PE ratio of -10.84 and a beta of 1.31. Pieris Pharmaceuticals has a twelve month low of $2.39 and a twelve month high of $6.04. The stock has a 50 day simple moving average of $4.91 and a two-hundred day simple moving average of $4.03.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.

Recommended Story: How Investors Use a Balance Sheet

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.